InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

- Current share price for ATX : $0.135

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$69 Change of Director's Interest Notice - Dr Christopher Burns 29 Aug 2023 4:50PM $0.088 $0.135 risen by 53.41%
$69 Notification regarding unquoted securities - ATX 29 Aug 2023 4:17PM $0.088 $0.135 risen by 53.41%
$69 Results of Annual General Meeting 24 Aug 2023 11:58AM $0.080 $0.135 risen by 68.75%
$69 CEO and MD Presentation to Annual General Meeting 24 Aug 2023 10:24AM $0.080 $0.135 risen by 68.75%
$69 ACCENT Trial Recruitment Update 2 Aug 2023 8:33AM $0.087 $0.135 risen by 55.17%
$69 ATX Quarterly Activities and Cashflow Reports - June 23 Qtr 31 Jul 2023 8:18AM $0.085 $0.135 risen by 58.82%
$69 Notice of Annual General Meeting/Proxy Form 21 Jul 2023 4:58PM $0.078 $0.135 risen by 73.08%
$69 ATX - Shareholder Newsletter July 2023 20 Jul 2023 9:52AM $0.081 $0.135 risen by 66.67%
$69 Application for quotation of securities - ATX 12 Jul 2023 5:24PM $0.084 $0.135 risen by 60.71%
$69 AMP945 International Nonproprietary Name Narmafotinib 21 Jun 2023 8:34AM $0.090 $0.135 risen by 50%
$69 Amplia AGM to be held Thursday 24 August 2023 19 Jun 2023 5:34PM $0.083 $0.135 risen by 62.65%
$69 Key to Corporate Governance Disclosures 31 May 2023 8:14AM $0.089 $0.135 risen by 51.69%
$69 2023 Corporate Governance Statement 30 May 2023 5:12PM $0.089 $0.135 risen by 51.69%
$69 Annual Report to Shareholders 30 May 2023 5:11PM $0.089 $0.135 risen by 51.69%
$69 AMP945 and FOLFIRINOX active in model of Pancreatic Cancer 29 May 2023 8:42AM $0.085 $0.135 risen by 58.82%
$69 Grant to collaborate with CSIRO Supplementary Announcement 23 May 2023 11:22AM $0.091 $0.135 risen by 48.35%
$69 Amplia receives grant to collaborate with CSIRO 22 May 2023 8:24AM $0.085 $0.135 risen by 58.82%
$69 ACCENT Trial Recruitment Progress 9 May 2023 11:44AM $0.100 $0.135 risen by 35%
$69 Quarterly Activities and Cashflow Reports - March 23 Qtr 26 Apr 2023 10:03AM $0.105 $0.135 risen by 28.57%
$69 First Patient Recruited to Cohort 3 of ACCENT Trial 19 Apr 2023 8:22AM $0.085 $0.135 risen by 58.82%
$69 Dose Escalation Approved in ACCENT Clinical Trial of AMP945 11 Apr 2023 12:17PM $0.090 $0.135 risen by 50%
$69 ACCENT Trial Recruitment Progress 28 Feb 2023 11:29AM $0.085 $0.135 risen by 58.82%
$69 ATX - US Conference Presentation 23 Feb 2023 4:55PM $0.089 $0.135 risen by 51.69%
$69 AmpliaTherapeutics - Lorne Cancer Conference Presentation 9 Feb 2023 8:16AM $0.089 $0.135 risen by 51.69%
$69 First Patient Recruited to Cohort 2 of Accent Trial 1 Feb 2023 11:23AM $0.090 $0.135 risen by 50%

226 - 250 of 540 results

Page 10 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.